TG Therapeutics, Inc. (TGTX) shares climbed 5.3% to $55.85 as of September 16, 2026, a significant gain from the prior close of $53.04. BestStocks flagged the session as a major change for TGTX. The move is tied to price move up. Below, we break down what changed for TGTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
TGTX climbed 5.3% to $55.85
TG Therapeutics, Inc. (TGTX) moved +5.14% from $53.12 to $55.85 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.6x the 5-day average, modestly elevated. TGTX earnings report expected 2026-11-02.
This summary describes the catalyst and move as first detected on Sep 16, 2026, 4:52 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
1.0×
Normal
Vs peers
—
No comparable peers
Market cap
$8.5B
NASDAQ Capital Market
Analyst target
$81
+44.1% vs price
Price chart
Aug 17 – Sep 16
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for TG Therapeutics, Inc. investors
For TG Therapeutics, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 5.3% price move. Weighing against that: TG Therapeutics, Inc. (TGTX) moved -8.92% from $50.69 to $46.17 on 2026-08-03; TGTX declined 3.74% after reporting second-quarter 2025 earnings with in-line Briumvi sales but missing profit expectations. Wall Street's consensus price target sits at $80.50, implying +44.1% upside from $55.85. BestStocks rates the overall signal quality low (58/100). With earnings roughly 47 days out, the next report is the most likely near-term test of the move.
TGTX price reaction
TGTX last traded at $55.85, up $2.81 (+5.30%) from the previous close of $53.04. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $49.28 and $56.90, and it currently sits about 86% of the way up that band.
Bullish and bearish analyst opinions on TG Therapeutics, Inc. (TGTX)
The consensus analyst price target on TG Therapeutics, Inc. (TGTX) is $80.50, 44.1% above the recent $55.85. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TGTX line up.
▲ The bullish case
+Wall Street's consensus price target of $80.50 implies +44.1% upside from $55.85.
+The Street's most bullish target is $83.00 (+48.6%).
+Material positive event.
+Strong 5.3% price move.
+TG Therapeutics, Inc. (TGTX) moved +3.44% from $48.22 to $49.88 on August 5, 2026.
▼ The bearish case
−TG Therapeutics, Inc. (TGTX) moved -8.92% from $50.69 to $46.17 on 2026-08-03.
−TGTX declined 3.74% after reporting second-quarter 2025 earnings with in-line Briumvi sales but missing profit expectations.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 16, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
TG Therapeutics, Inc. (TGTX) moved -3.27% from $55.71 to $53.89 on 2026-09-11. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the decline occurred on typical trading activity.
Material / Earnings2026-09-01+3.3%
TG Therapeutics, Inc. (TGTX) moved +6.14% from $52.84 to $56.09 on September 1, 2026, on volume 2.3x the 5-day average. The move was driven by unconfirmed takeover speculation from M&A blog Betaville suggesting potential interest from a larger biopharma suitor, combined with investor enthusiasm over the company's raised 2026 revenue guidance for its flagship multiple sclerosis drug Briumvi to approximately $950 million and H.C. Wainwright's reaffirmed buy rating.
Material / Earnings2026-08-28-3.2%
TG Therapeutics, Inc. (TGTX) moved -2.88% from $55.53 to $53.93 on 2026-08-28. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The decline occurred on light trading volume at 41% of the 5-day average.
Material / Earnings2026-08-24+3.2%
TG Therapeutics, Inc. (TGTX) moved +5.30% from $53.19 to $56.01 on 2026-08-24 following unverified M&A buyout speculation reported by market intelligence blog Betaville, which indicated an unnamed mid-to-large biopharma company may be pursuing an acquisition. The move was amplified by strong underlying fundamentals: in August the company reported Q2 2026 U.S. net product revenue for BRIUMVI reached $227.7 million (up 64% year-over-year) and raised full-year total global revenue guidance to approximately $950 million.
Material / Earnings2026-08-21+7.3%
TGTX moved +7.68% from $50.39 to $54.26 on 2026-08-21, driven by positive momentum around Briumvi's commercial performance and pipeline optimism. News reports cited strong market adoption and revenue growth expectations for its multiple sclerosis drug Briumvi, enthusiasm for subcutaneous at-home injection development, and institutional buying interest including large stake purchases by Bank of America.
Material / Earnings2026-08-14+1.7%
TG Therapeutics, Inc. (TGTX) moved +3.11% from $47.27 to $48.74 on 2026-08-14. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move occurred on routine trading activity.
Material / Earnings2026-08-13-3.2%
TGTX moved -3.54% from $49.70 to $47.94 on 2026-08-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, indicating modestly elevated trading activity accompanying the decline.
Filings2026-08-05+2.3%
TG Therapeutics, Inc. (TGTX) filed a 10-Q on August 5, 2026, covering its most recent quarterly results.
Upcoming catalysts & outlook
Next earnings
2026-11-02 (est.)
in 47 days
10-Q Filing (est.)
2026-11-04
Medium impact
Thesis shift
Bullish Shift
bullish signal
Risk level
High
from change events
Frequently asked questions about TGTX
Why did TG Therapeutics, Inc. (TGTX) stock move?
TGTX climbed 5.3% to $55.85. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did TGTX stock rise?
TGTX gained 5.30% ($2.81) versus the prior close of $53.04, last trading at $55.85 on 1.0× average volume.
When is TG Therapeutics, Inc.'s next earnings date?
TGTX's next earnings report is estimated for 2026-11-02 — about 47 days away.
What is the analyst price target for TGTX?
The consensus analyst price target for TGTX is $80.50, about 44.1% above the current $55.85. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks TGTX
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for TGTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 16, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
